Clinical Trial Search

Primary: Changes in Endocrine Disrupting Chemical (EDC) Levels as Measured by the Post-intervention Value Minus the Baseline Value. — 5.83; 18.43; 56.94; 75.30 ng/ml — p=<0.05

Primary: VAS Scores as Measures of Profoundness of Pulpal Anesthesia — 3.1; 1.2 Score on a scale

Primary: Sun Protection Habits Index — 2.9; 3 scores on a scale

Primary: Perceived Stress Scale — -3.2 units on a scale

Primary: Self-efficacy to Quit Smoking — 2.61; 2.76; 2.62; 2.56 score on a scale — p=0.60

Primary: Number of Subjects With a Cardiopulmonary Event — 145 Participants

Primary: Average Number of Parathyroid Glands Identified With High Confidence Per Patient — 3.1; 2.7 parathyroid glands — p=0.04

Primary: Recruitment — 30 Participants

Primary: Number of Oocytes Retrieved — 11.1; 9.6 Oocytes — p=0.0185

Primary: Reduction of Worst Itch in Atopic Dermatitis — -3.6; -3.5 units on a scale

Primary: Number of Participants With Adverse Events Related to Intranasal MSC Treatment (Safety and Tolerability) in the Acute Setting. — 10; 0; 9; 1 Participants

Primary: Death or Inability to Walk 10 Feet or Across a Room Without Human Assistance — 132; 132 Participants

Primary: Change in Neuropathy Impairment Score (NIS) at Month 12 for ATTRv — 1.6 Change in score*months

Primary: Safety of TNP-2092 by Assessment of the Number of Participants With Adverse Events (AEs) — 6; 6; 7; 8 participants

Primary: Propofol Requirements With Pre-treatment of Dexmedetomidine With Children Who do Not Receive Dexmedetomidine. — 0.4; 0.23 mg/kg/min